medRxiv preprint doi: https://doi.org/10.1101/2020.12.14.20248212; this version posted December 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

TITLE
Active vaccine safety surveillance via a scalable, integrated system in Australian
pharmacies.
AUTHOR INFORMATION
Corresponding Author
Sandra M SALTER PhD
School of Allied Health, Faculty of Health and Medical Sciences
The University of Western Australia
M315, 35 Stirling Highway, Perth WA 6009. Australia.
Email: sandra.salter@uwa.edu.au
ORCID ID: https://orcid.org/0000-0002-5840-6797
Author order
Sandra M Salter, Gurkamal Singh, Lisa Nissen, Kevin Trentino, Kevin Murray, Kenneth Lee,
Benjamin Kop, Ian Peters, Alan Leeb.
Author Details
Sandra M SALTER PhD
School of Allied Health
The University of Western Australia
M315, 35 Stirling Highway, Perth WA 6009. Australia.
Email: sandra.salter@uwa.edu.au
ORCID ID: https://orcid.org/0000-0002-5840-6797
Gurkamal SINGH BSc
School of Allied Health
The University of Western Australia
M315, 35 Stirling Highway, Perth WA 6009. Australia.
Email: 21713453@student.uwa.edu.au
Lisa NISSEN PhD
Queensland University of Technology
Level 9, Q Block Room, 911
Brisbane, QLD 4000, Australia
Email: l.nissen@qut.edu.au
ORCID ID: https://orcid.org/0000-0001-5826-4605
Kevin TRENTINO MPH
School of Population and Global Health
The University of Western Australia, Perth WA, 6009. Australia
Email: kevin.trentino@uwa.edu.au
ORCID ID: https://orcid.org/0000-0002-8768-9263
Kevin MURRAY PhD
School of Population and Global Health
The University of Western Australia, Perth WA, 6009. Australia
NOTE: This
preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Email:
kevin.murray@uwa.edu.au

1

medRxiv preprint doi: https://doi.org/10.1101/2020.12.14.20248212; this version posted December 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

ORCID ID: http://orcid.org/0000-0002-8856-6046
Kenneth LEE PhD
School of Allied Health
The University of Western Australia
M315, 35 Stirling Highway, Perth WA 6009. Australia.
Email: kenneth.lee@uwa.edu.au
ORCID ID: https://orcid.org/0000-0003-3022-4868
Benjamin KOP BSc
School of Allied Health
The University of Western Australia
M315, 35 Stirling Highway, Perth WA 6009. Australia.
Email: 21956982@student.uwa.edu.au
Ian PETERS BSc
Illawarra Medical Centre
29 Illawarra Cres S, Ballajura WA 6066, Australia
Email: ian.peters@datavation.com.au
Alan LEEB FRACGP
Illawarra Medical Centre
29 Illawarra Cres S, Ballajura WA 6066, Australia
Email: alan@illawarramedical.com.au
Competing Interest Declaration
SMS, AL, KL, LN, IP report a grant from the J.M. O’Hara Research Fund of the
Pharmaceutical Society of Western Australia (PSWA) to conduct this research. AL and IP are
Directors of SmartXData, of which SmartVax is a subsidiary. IP has previously received
funding from SmartX Data for database development. The authors declare no other conflicts.
ETHICS STATEMENT
Approval to conduct this research was obtained from the Human Research Ethics Committee
of The University of Western Australia.
AUTHORS’ CONTRIBUTIONS
SMS conceptualized, designed and supervised the study, raised funding for the study, assisted
with data collection and analysis, interpreted the results, wrote the draft versions and
prepared the final version of the manuscript. GS performed the literature review, assisted
with data collection and interpretation of the results, and reviewed the manuscript. LN raised
funding for the study, assisted with study design and recruitment, interpreted the results, and
reviewed the manuscript. KT assisted with data collection, verified the underlying data,
performed data analysis, interpreted the results, prepared all charts, wrote part of the draft
versions, and reviewed the manuscript. KM assisted with data collection, verified the
underlying data, assisted with data analysis, interpreted the results, and reviewed the
manuscript. KL assisted with study design, raised funding and reviewed the manuscript. BK
performed the literature review, assisted with data collection and interpretation of the results,
and reviewed the manuscript. IP provided intellectual and technical input, provided access to
active surveillance, assisted with study supervision, data collection and analysis, interpreted
the results and reviewed the manuscript. AL provided intellectual input, provided access to

2

medRxiv preprint doi: https://doi.org/10.1101/2020.12.14.20248212; this version posted December 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

active surveillance, assisted with study supervision, data collection and analysis, interpreted
the results and reviewed the manuscript. All authors have read and approved the final version
of the manuscript.
FINANCIAL SUPPORT
The research was supported by a research grant provided by the J.M. O’Hara Research Fund
of the Pharmaceutical Society of Western Australia.
ACKNOWLEDGMENTS
We are extremely grateful for the tremendous in-kind support provided by SmartVax and
MedAdvisor International and for their unending commitment and tireless efforts to conduct
and complete the study in the year 2020 – a year of significant disruption on a global scale.
We would like to thank Ms Dani Li, Mr Craig Schnuriger, Mr Weyn Ong, Mr Daniel Smith,
Ms Karin Orlemann, Ms Danae Perry, Ms Rachel Nesaraj and Mr Nicolas Bchara for their
continued efforts and contributions.
AVAILABILITY OF DATA AND MATERIALS
Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and supplementary material) are available upon reasonable
request.
Proposals for data should be directed to Sandra Salter via ORCID: https://orcid.org/00000002-5840-6797.
To gain access to data, users will need to sign a data access agreement. Reuse is permitted
under the following conditions: meta-analyses of adverse events following immunisation in
pharmacies.
DISCLAIMER
The views expressed in the submitted article represent the original interpretations and
opinions of the authors and are not an official position of any affiliated institution or funder.
KEYWORDS
vaccine safety, active surveillance, pharmacy, immunisation, vaccination

3

medRxiv preprint doi: https://doi.org/10.1101/2020.12.14.20248212; this version posted December 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

ABSTRACT
Introduction: Active vaccine safety surveillance will be critical to COVID-19 vaccine
deployment. Pharmacists have been identified as potential immunisers in COVID-19 policies,
yet there are no reported active surveillance systems operating in pharmacies. We integrated
an established participant-centred active vaccine safety surveillance system with a cloudbased pharmacy immunisation-recording program. We measured adverse events following
immunisation (AEFI) reported via the new surveillance system in pharmacies, and compared
these to AEFI reported via an existing surveillance system in non-pharmacy sites (general
practice and other clinics).
Methods: A prospective cohort study of individuals>10 years receiving influenza
immunisations from 22 pharmacies and 90 non-pharmacy sites between March and October,
2020, in Australia. Active surveillance was conducted using SMS and smartphone
technology, via an opt-out system. Multivariable logistic regression (including a subgroup
analysis of participants over 65 years) was used to assess differences in proportions of AEFI
between participants immunised in pharmacies compared to non-pharmacy sites, adjusting
for confounders of age, sex, and influenza vaccine brand.
Results: Of 101,440 influenza immunisation participants (6,992 from pharmacies; 94,448
from non-pharmacy sites), 77,498 (76.4%) responded; 96.1% (n=74,448) within 24 hours.
Overall, 4.8% (n=247) pharmacy participants reported an AEFI, compared with 6.0%
(n=4,356) non-pharmacy participants (adjusted odds ratio: 0.87; 95% confidence interval:
0.76 to 0.99; p=0.039). Similar proportions of AEFIs were reported in pharmacy (5.8%;
n=31) and non-pharmacy participants (6.0; n=1617) aged over 65 years (adjusted odds ratio:
0.94, 95% confidence interval: 0.65 to 1.35; p=0.725).
Conclusion: High and rapid response rates demonstrate good participant engagement with
active surveillance in both pharmacy and non-pharmacy participants. Significantly fewer

4

medRxiv preprint doi: https://doi.org/10.1101/2020.12.14.20248212; this version posted December 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

AEFIs reported after pharmacist immunisations compared to non-pharmacy immunisations,
with no difference in older adults, suggests different cohorts attend pharmacy and nonpharmacy immunisers. The integrated pharmacy system is rapidly scalable across Australia
with global potential.

5

medRxiv preprint doi: https://doi.org/10.1101/2020.12.14.20248212; this version posted December 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

SUMMARY POINTS
What is already known?
•

Many countries use post-licensure surveillance systems to monitor vaccine safety
after a vaccine has been released onto the market.

•

Passive surveillance systems operate in most countries but are limited by underand/or biased reporting, and delayed detection of safety signals.

•

Active surveillance systems have been reported for different sectors in Australia, the
United States and Canada but there are no pharmacy-based active surveillance
systems world-wide, and there is little evidence of rates of adverse events following
immunisation (AEFI) in pharmacy.

What are the new findings?
•

We successfully linked two established platforms: an active vaccine safety
surveillance system that integrates with national surveillance networks in Australia,
with a cloud-based pharmacy immunisation-record system to develop an automated
active vaccine safety surveillance system for pharmacies.

•

Through active surveillance of 101,440 influenza immunisations between March and
October, 2020 (6,992 from pharmacies, and 94,448 from non-pharmacy sites), fewer
pharmacy participants reported any AEFI compared to non-pharmacy participants.

What do the new findings imply?
•

Pharmacists are safe immunisers who may capture patients not seen in general
practice or other clinics.

•

Our integrated pharmacy system is rapidly scalable, links with existing surveillance
systems that integrate with the World Health Organization and has global potential.

6

medRxiv preprint doi: https://doi.org/10.1101/2020.12.14.20248212; this version posted December 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

•

This study provides a proven infrastructure of crucial importance to maintain public
safety, to promote confidence in vaccine safety, and to assist with COVID-19 vaccine
uptake in a safe manner.

7

medRxiv preprint doi: https://doi.org/10.1101/2020.12.14.20248212; this version posted December 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

INTRODUCTION
The novel SARS-CoV-2 virus and resulting COVID-19 pandemic has created health and
economic crises of unprecedented proportions. Ultimately, only a safe and effective vaccine
can mitigate the severe, disruptive consequences of COVID-19. At the time of writing, more
than 200 vaccine candidates are under accelerated development – more than 50 of them under
clinical evaluation (phase I, II or III human trials).[1]
Multiple vaccines are expected to be approved under individual government licensure rules
and made available equitably through various initiatives including the COVAX Facility.[2]
However, the unique and urgent need to deploy COVID-19 vaccines must be balanced
against rapid vaccine development and limited safety data.[3-5]
Adverse events following immunisation (AEFI) can compromise public safety, undermine
patient and immuniser confidence in any vaccine, and trigger markedly reduced rates of
immunisation.[6] In context, vaccine safety surveillance extends beyond essential
pharmacovigilance: it is critical to the deployment and continued uptake of a COVID-19
vaccine, as well as to ongoing success of existing immunisation programs.
Passive surveillance is the cornerstone of vaccine pharmacovigilance but relies on selfreporting of AEFIs by patients and healthcare professionals, and is limited by under- and/or
biased reporting, and delayed detection of safety signals.[7,8] Active surveillance, by
contrast, directly contacts patients after immunisation and can capture adverse event data
from large numbers of vaccinees in near-real time.[9] Direct, participant-centred
technological approaches, in particular those that are automated and integrated with larger
networked systems,[8,10,11] offer broad scope and immediate promise for COVID-19
vaccine surveillance.
SmartVax is an established, participant-centred, automated active surveillance program that
employs short message service (SMS) and smartphone technology,[8] and is a key element of

8

medRxiv preprint doi: https://doi.org/10.1101/2020.12.14.20248212; this version posted December 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Australia’s active vaccine safety monitoring system, AusVaxSafety.[12] This relationship
facilitates sharing of Australia’s AEFI data with national agencies such as the National
Centre for Immunisation Research and Surveillance (NCIRS) and the Therapeutic Goods
Administration,[13] and with international agencies, notably the World Health
Organization.[13]
Pharmacists have an established role in provision of influenza and other vaccines,[14,15] and
in Australia, are also authorised to immunise patients in locations outside pharmacies (such
as aged care facilities or schools).[16,17] Pharmacists have been identified as potential
immunisers in COVID-19 vaccination policies,[18-20] yet, globally, there are no reported
active surveillance systems operating in pharmacies. Given the important role pharmacists
will play in COVID-19 immunisation, and their accessibility across cities, towns and remote
regions, a broad-scale active surveillance system, with agility to adapt as new vaccines are
approved, and capacity to operate across a range of geographical settings should be
implemented. A system that is automated and linked directly to pharmacy software offers a
simple, fail-safe option for surveillance, with little impact on pharmacist workload.
MedAdvisor® is a global, cloud-based, automated application for Pharmacy,[21] used widely
in Australia. The MedAdvisor PlusOne® platform is used by pharmacists to record
immunisation encounters, and automatically reports immunisations to the Australian
Immunisation Register (AIR).
In order to develop a participant-centred, automated active vaccine surveillance system for
pharmacies, suitable for monitoring any vaccine delivered by pharmacists, we integrated
SmartVax with MedAdvisor®. In this study we sought to test integration of the system
through measurement of AEFI in pharmacies compared to existing non-pharmacy active
surveillance sites, during the 2020 influenza immunisation season in Australia.

9

medRxiv preprint doi: https://doi.org/10.1101/2020.12.14.20248212; this version posted December 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

METHODS
Study design, participants and setting
We conducted a prospective cohort study of participants receiving immunisations from
pharmacist and non-pharmacist providers in Western Australia between March and October
2020. Participants were consecutive individuals who self-selected to receive an influenza
immunisation at any of 112 locations in Western Australia. This included 22 pharmacies
recruited for the purposes of this study, and 90 non-pharmacy immunisation sites
participating in ongoing active surveillance as part of usual practice.
The aforementioned 22 pharmacies were recruited for SmartVax integration in March 2020
via: direct email to all Western Australian (WA) community pharmacies using the
MedAdvisor PlusOne® platform to record immunisations; promotion through professional
newsletters and Facebook pages; and via a media release by The University of Western
Australia.[22] Site and pharmacist immuniser consent were obtained prior to enrolling each
pharmacy into the study. All pharmacists were experienced in using the MedAdvisor
PlusOne® platform. Training on the SmartVax system and the study was provided to all
pharmacists prior to data collection. All pharmacies received printed material to inform
participants of the study consent process, with an explanatory poster for display in the
immunisation consulting room.
Non-pharmacy sites (including general practice, university, community and local government
clinics) participating in active surveillance through SmartVax have been previously
described.[8,23]
SmartVax was used to actively monitor and record AEFIs between March and October 2020.
Immunisations recorded in the MedAdvisor PlusOne® system at each pharmacy were
automatically batched and sent to SmartVax via a push application programming interface
(API) each day. The API was used as a centralised mechanism to submit all records of

10

medRxiv preprint doi: https://doi.org/10.1101/2020.12.14.20248212; this version posted December 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

vaccination encounters recorded across the MedAdvisor® cloud application (for participating
pharmacies) to the SmartVax server. Immunisation encounters recorded in the non-pharmacy
sites were automatically extracted by SmartVax program at each site, each day.
SmartVax sent a series of automated SMS text messages to all participants three to five days
after immunisation, to enquire if any AEFIs had been experienced. ‘Yes’ responders received
a second SMS to enquire whether medical attendance had been sought, followed by a third
SMS with a link to a short survey to identify the nature, duration and severity of all reactions
(Figure 1). People who responded ‘No’ did not receive a second or third SMS.
We also performed an audit of the integrated pharmacy system to determine the number of
immunisation encounters recorded in the MedAdvisor PlusOne® program that were 1)
captured in the batch process, 2) made available for SmartVax surveillance, and 3) ultimately
underwent surveillance.
Ethics approval for this study was obtained from The University of Western Australia Human
Research Ethics Committee (RA/4/20/5907).
Variables
The primary outcome of interest was any adverse event following immunisation (AEFI).
Secondary outcomes included AEFIs resulting in medical attendance, and adverse event
profile as reported in the survey (fever, pain, swelling, tired, irritable, sleep, rash, headache,
vomiting, diarrhoea, and other). In addition to data collected on adverse events, SmartVax
captured information on participant age, sex, and influenza vaccine brand. Pharmacists in
WA are authorised to administer influenza vaccines to people 10 years and older, so we
included age ≥ 10 years in our analyses. In order to compare adverse events reported by
participants immunised in pharmacies to non-pharmacy sites, our exposure variable of
interest was immunisation provider.

11

medRxiv preprint doi: https://doi.org/10.1101/2020.12.14.20248212; this version posted December 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Data for the analysis were obtained from the SmartVax system, which includes participant
demographic data, their responses to SMS messages, and where relevant, survey results.
Statistical methods
Summary statistics for each immunisation location were provided and comparisons between
pharmacy and non-pharmacy immunisations were made using the independent samples t-test
(or Mann-Whitney test for non-normal data) for continuous variables, and chi-square tests for
categorical variables. A comparison of participants reporting adverse events following
influenza immunisation was made in unadjusted analysis using a chi-square test. Logistic
regression was used to assess differences in proportions of adverse events between
participants immunised in pharmacies and participants immunised at non-pharmacy sites,
adjusting for confounders of age, sex, and influenza vaccine brand in a multivariable model.
We conducted a sub-group analysis of participants 65 years and over. Only complete records
(age, sex and vaccine brand) were included in the analyses. The significance level was set at
0.05.
All statistical analyses were conducted using R [version 3.5.3; The R Foundation for
Statistical Computing]. Results are reported according to STROBE checklist for cohort
studies.[24]

12

medRxiv preprint doi: https://doi.org/10.1101/2020.12.14.20248212; this version posted December 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

RESULTS
We actively monitored 101,440 complete influenza immunisation encounters between 10
March 2020 and 17 October 2020 (6,992 from pharmacies, and 94,448 from non-pharmacy
sites). A total 5,100 (72.9%) pharmacy participants and 72,398 (76.7%) non-pharmacy
participants responded to SMS1, providing 77,498 immunisation encounters for analysis
(Figure 1).
The mean (SD) age of participants was 51.5 (21.02) years, and 58·3% (n=45,186) were
female. The most common influenza vaccines administered were FluQuadri 27.1%
(n=27,491), Fluad Quad 26.6% (n=26,934), and Afluria Quad 10.3% (n=10,491). Overall,
96.1% (n=74,448) of responders replied within 24 hours of receiving SMS1, with 98.7%
(n=76,485) responding within 72 hours. Of all responders, 5.9% (n=4,603) reported an
adverse event following immunisation.
We present the characteristics of participants immunised in Table 1.

13

Figure 1. Flow diagram of patient identification for the study cohort.
Immunisation encounters identified by SmartVax
(n =101,440)
Pharmacy immunisations
(n = 6992)

Non-pharmacy* immunisations
(n = 94,448)

SMS 1 sent
(n = 6992)
Did not respond
(n=1892)
Responded YES Responded NO
(n = 247)
(n = 4853)

SMS 1: [Patient name],
thanks for choosing to
have a vaccination. We
would like to know if
there were any
reactions. Please reply
with “Y” for Yes, “N” for
No or “STOP” to opt out
SMS 2: As a result of the
vaccination reaction, did
you visit a doctor,
medical centre, after
hours service, or
hospital emergency
dept? Please answer Y or
N only.

SMS 2 sent
(n = 247)
Did not respond
(n=21)
Responded YES Responded NO
(n = 4)
(n = 222)
SMS 3 sent
(n = 247)
Responded
(n = 184)

Did not respond
(n = 63)

SMS 3: Thanks for
responding, [patient
name]. Could you please
complete a 2 minute
survey here:
http://survey.smartvax.c
om.au/?id=MAV&sv=1

SMS 1 sent
(n = 94,448)
Did not respond
(n=22,050)
Responded YES Responded NO
(n = 4356)
(n = 68,042)
SMS 2 sent
(n = 4356)
Did not respond
(n=625)
Responded YES Responded NO
(n = 182)
(n = 3459)

*Non-pharmacy sites included general practices, university clinics, community clinics and local government clinics

SMS 3 sent
(n = 4356)
Responded
(n = 3007)

Did not respond
(n = 1349)

medRxiv preprint doi: https://doi.org/10.1101/2020.12.14.20248212; this version posted December 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Table 1. Characteristics of influenza immunisation encounters by location.
Location
Pharmacy
(n=5,100)
3016 (59.1)
46.52 (17.02)
10,99

Non-pharmacy
(n=72,398)
p-value
Sex, female (%)
42170 (58.2)
0.218
Age, years (mean (SD))
51.90 (21.23) <0.001
Age, years (minimum, maximum)
10,101
Age group, years
<0.001
<18
371 (7.3)
7314 (10.1)
18 - 64
4196 (82.3)
38042 (52.5)
>= 65
533 (10.5)
27042 (37.4)
Vaccine brand (%)
<0.001
Afluria Quad
1974 (38.7)
8517 (11.8)
Fluad Quad
514 (10.1)
26420 (36.5)
Fluarix Tetra
1119 (21.9)
6862 (9.5)
FluQuadri
914 (17.9)
26578 (36.7)
Fluzone High-Dose
0 (0.0)
2 (0.0)
Influvac Tetra
567 (11.1)
1416 (2.0)
Vaxigrip Tetra
12 (0.2)
2600 (3.6)
SMS response time, minutes (median [IQR])*
13 [3,72]
14 [4,70]
0.006
Responses received to SMS1 within 24 hours (%) 4939 (96.8)
69549 (96.1)
0·006
Values are count (proportion), mean (SD) or median (IQR) as indicated. P-values are
calculated from the chi-square test for categorical variables and the independent samples ttest for continuous variables. * The p-value for SMS response time was calculated using the
Mann-Whitney Wilcoxon Test.

Participants receiving influenza vaccinations at pharmacies had a lower mean age (46.5 vs.
51.9 years; p<0.001), with 10.5% (n=533) aged 65 years and over compared with 37.4%
(n=27,042) at non-pharmacy sites. Pharmacists were more likely to administer Afluria Quad®
(Seqirus) and Fluarix Tetra® (GlaxoSmithKline), while non-pharmacist immunisers were
more likely to administer Fluad Quad® (Seqirus) and FluQuadri® (Sanofi-Aventis) (p<0.001).
Response times to the first SMS were similar between groups, with a median (IQR) of 13
minutes (3 to 72 minutes) for pharmacy, and 14 minutes (4 to 70 minutes) for non-pharmacy
vaccinees.

14

medRxiv preprint doi: https://doi.org/10.1101/2020.12.14.20248212; this version posted December 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Rate of any adverse event
The unadjusted proportion of any adverse event differed significantly between participants
immunised at pharmacies and those immunised elsewhere. Of those immunised at
pharmacies, 4.8% (n=247) reported an adverse event, compared with 6.0% (n=4,356) for
those immunised at non-pharmacy sites (unadjusted odds ratio = 0.80, 95% confidence
interval 0.70 to 0.91; p=0.001). After adjusting for age, sex, and vaccine brand, participants
immunised at pharmacies reported fewer adverse events, compared to participants immunised
in non-pharmacy sites (odds ratio (OR)=0.87, 95% confidence interval (95% CI): 0.76 to
0.99, p=0.039).
Adverse events resulting in medical attendance
Participants reporting any adverse event were sent a second SMS asking if they visited a
doctor, medical centre, after-hours service, or hospital emergency department as a result of
their vaccination reaction. We excluded 646 (0.8%) encounters from this analysis, as they did
not respond to the second SMS.
Of participants immunised at pharmacies, 0.1% (n=4) reported seeking medical care
following an adverse event compared with 0.3% (n=182) of participants immunised at nonpharmacy sites (p=0.021). After adjusting for age, sex, and vaccine brand, participants
immunised at pharmacies reported less adverse events for which medical attendance was
sought, compared to participants immunised at non-pharmacy sites (OR=0.35, 95% CI: 0.13
to 0.97, p=0.042).
Adverse event profile
The most common adverse events reported after immunisation in pharmacies were pain
(2.0%; n=104), tiredness (1.9%; n=95), and headache (1.7%; n=88). The most common
adverse events reported after immunisation in non-pharmacy sites were pain (2.3%; n=1660),
tiredness (1.9%; n=1362), and swelling (1.5%; n=1121), Figure 2. A total of 1.4% (n=68)

15

medRxiv preprint doi: https://doi.org/10.1101/2020.12.14.20248212; this version posted December 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

pharmacy and 1.2% (n=778) non-pharmacy participants selected ‘other’ AEFI, and included
a text description of the reaction. The majority of these reactions were described as aches,
dizziness, muscle and joint pain, cold symptoms, sore throat, and nausea; Supplementary
Tables 1 and 2. Figure 3 presents odds ratios for adverse event profile after adjusting for age,
sex, and vaccine brand, comparing participants immunised at pharmacies to those immunised
at non-pharmacy sites.
65 years and over sub-analysis
Of participants aged 65 years and over, 5.8% (n=31) immunised at pharmacies reported any
adverse event compared with 6.0% (n=1617) for those immunised at non-pharmacy sites
(OR= 0.97, 95% CI: 0.67 to 1.40; p=0.875). After adjusting for age, sex and vaccine brand,
participants immunised at pharmacies reported similar proportions of any adverse events
when compared to participants immunised at non-pharmacy sites (OR=0.94, 95% CI: 0.65 to
1.35, p=0.725). No participants 65 years and over who were immunised at pharmacies
reported seeking medical care following an adverse event, compared with 0.3% (n=72) of
participants immunised at non-pharmacy sites.
Audit of the integrated pharmacy system
Of 11,008 immunisations given in the pharmacies, 10.0% (n=1106) chose not to participate
in surveillance, and 71.0% (n=7821) were captured in the API batch process. Of these, 95.6%
(n=7475) were available for SmartVax surveillance, and 92.4% (n=7230) were sent SMS1.
We identified in July 2020 that 20.1% (n=2081) records for participants without a recorded
sex had not transferred via the API. This was rectified and subsequently 100% of records
(including records without sex) were successfully transferred via the API (Figure 4).

16

3.0

Pharmacy
Other

Adverse event (%)

2.5

2.3
2.0

2.0

1.9

1.9
1.7

1.5

1.5

1.5

1.4
1.2

1.1
0.9

1.0
0.6

0.6

0.5

0.3

0.4

0.4
0.2

0.2

0.1

0.1

0.1

0.2

0.0
Fever

Pain

Swelling

Tired

Irritable

Sleep

Rash

Headache Vomiting Diarrhoea

Other

Reported Outcome

Adjusted Odds
Ratio (95% CI)

Any adverse event

0.86 (0.75, 0.99)

Fever

0.74 (0.51, 1.07)

Pain

0.98 (0.79, 1.21)

Swelling

0.78 (0.59, 1.04)

Tired

1.04 (0.83, 1.3)

Irritable

0.82 (0.49, 1.36)

Sleep

0.69 (0.44, 1.08)

Rash

0.83 (0.39, 1.75)

Headache

1.29 (1.03, 1.63)

Vomiting

0.55 (0.2, 1.55)

Diarrhoea

0.64 (0.25, 1.62)

Other

1.24 (0.96, 1.61)

Medical attendance

0.35 (0.12, 0.96)
0.12

0.18

0.25

0.35

0.50
0.71
1.0
1.41
2.0
<−−−Favours pharmacy Favours non−pharmacy sites−−−>

Figure 4: Audit of data flow in the integrated pharmacy active vaccine safety surveillance system

July 20 – September 16, 2020

April 9 – July 19, 2020

22 Pharmacies – enrolled
consecutively from April 9 to May 4

Immunisation encounters recorded in
MedAdvisor PlusOne software in Pharmacies
n=10,375

22 Pharmacies ongoing in the pilot

Immunisation encounters recorded in
MedAdvisor PlusOne software in Pharmacies
n=633b

Participants
opted out of
the study
n=1,040

Participants
opted out of
the study
n=66

Immunisation encounters
eligible to be sent to SmartVax
n=9,335

Immunisation encounters
eligible to be sent to SmartVax
n=567

Records with
missing sex excluded
from transfer
n=2,081

Records with
missing sex included
in transfer
n=148

Unique API submissions to
SmartVax n=7,254

Unique API submissions to SmartVax
n=567

Records entered latea
n=282

Records entered latea
n=64

SMS1 sent by SmartVax
n=6972

SMS1 sent by SmartVax
n =503

Invalid mobile
number/SMS failed
n=221

Invalid mobile
number/SMS failed
n=24

Total SMS 1 sent to Pharmacy participants
n=7230
Records excluded from analysis:
Not influenza vaccine: n=155
Age<10 years: n=5
Sex not recorded: n=148
Complete records for SMS1 (age, sex, vaccine brand)
n=6992
a.

b.

SmartVax automatically monitors all encounters three business days after immunisation. Therefore encounters entered to
MedAdvisor PlusOne more than three business days after immunisation did not receive SMS1. This scenario occurred in
pharmacies with a paper-to-electronic recording system. These encounters still transferred via the API but did not meet criteria
for automatic surveillance.
Unseasonably high demand for influenza vaccination early in the season resulted in low numbers of immunisations after July.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.14.20248212; this version posted December 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

DISCUSSION
Active surveillance systems, particularly those that integrate new technologies with current
vaccine surveillance systems,[3,25] will be vital to maintain public health and confidence, in
what may be the world’s biggest immunisation program in history: global immunisation
against COVID-19. This study is the first in the world to implement and evaluate active
surveillance of adverse events following immunisation (AEFI) in pharmacies. Through
integration of established active vaccine surveillance and cloud-based pharmacy software
systems, we developed a robust, rapidly scalable, automated, user-friendly, large scale AEFI
monitoring system.

There was a high (73%) and rapid response to active surveillance following influenza
immunisation in pharmacies (median 13 minutes; 96% within 24 hours); similar to responses
observed in non-pharmacy sites, both in this study and previously.[8,23] While the profile of
adverse events reported after pharmacy-based immunisations was similar to that reported
after immunisation in non-pharmacy sites, there were significantly fewer adverse events
overall reported from participants immunised in pharmacies compared to those immunised in
non-pharmacy sites, including general practice and other clinics. After adjusting for age,
gender, and vaccine brand this difference was still significant, albeit clinically small. As
participants immunised in pharmacies were significantly younger than those in non-pharmacy
sites, it is possible that more complex or sicker participants visited non-pharmacy
immunisers. However, there was no difference in overall adverse events observed in our
subanalysis of the over 65 years age group, whom we might expect to have more
comorbidities or be sicker. Notably, a surge in demand for early influenza vaccination in
2020, means we did not capture all participants immunised in participating pharmacies, as
our integrated system was activated a month after pharmacy vaccinations began. This could

17

medRxiv preprint doi: https://doi.org/10.1101/2020.12.14.20248212; this version posted December 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

have included sicker patients of any age. The relationship with the immuniser, anticipation of
AEFI, or sense of obligation to report even minor reactions may be different for people
attending pharmacies and non-pharmacy sites, but we did not measure this. Furthermore,
each site can and does immunise patients opportunistically. Such immunisation may, by
default, affect the cohort attending and their perception of AEFIs: people opportunistically
immunised in non-pharmacy sites (including general practice) may perceive themselves to be
sicker and be more inclined to report AEFIs, although we did not measure the proportion of
booked vs. opportunistic immunisations. Regardless, given response rates and time to
respond were similar between groups, the reason for the observed difference and whether it is
a true effect remains unclear. Even if the difference is true, it may simply represent different
cohorts being immunised in different sites: this in itself is of benefit as it indicates
pharmacies may capture a different set of people who may otherwise not seek immunisation.
Importantly, engagement with the integrated pharmacy system was observed in 5100
participants (aged 10-99 years) across 22 pharmacies, illustrating that age was not a barrier to
pharmacy vaccination, nor the technology used in the system.

This study has the potential to change practice immediately. There are two cloud-based
platforms used in Australia to record vaccination encounters, each of which has the capacity
to automatically upload the immunisation record to the Australian Immunisation Register
(AIR),[26] yet until now there was no structured surveillance system in pharmacy and no
mechanism to identify reactions once patients left the pharmacy. Through this study, active
vaccine safety surveillance is now instantly scalable to thousands of pharmacies in Australia
and can monitor patients previously out of reach. Furthermore, there is potential for global
scalability given the cloud-based pharmacy software integrated in this study, MedAdvisor,
has an international presence. This may be particularly useful for pharmacies in countries

18

medRxiv preprint doi: https://doi.org/10.1101/2020.12.14.20248212; this version posted December 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

where there does not appear to be published evidence of ongoing active surveillance systems,
for example, the United Kingdom.[27]

Beyond this, proposed changes to legislation requiring all vaccination providers to report
vaccines given to the AIR[28] means all pharmacy platforms will also have capacity to report
to the SmartVax API, extending coverage of surveillance. Significant economies of scale are
achieved through the pharmacy integration: technical support, program updates and
modifications to surveillance parameters can be completed efficiently in either component of
the integrated system and quickly activated at all participating sites. The system also has
potential for growth: in research, to link our surveillance data to national or state based
administrative datasets for long term surveillance and comparison of long term outcomes
against early reported AEFI and SARS-CoV-2 infection; in surveillance, to automatically
extract additional data such as medication lists, for incorporation in surveillance analyses.

Connection through the integration to AusVaxSafety, the principal Australian AEFI active
surveillance system, means pharmacy AEFI can be included in publicly reported surveillance
data, ensuring open and transparent monitoring. In context of high social media-led
disinformation campaigns about vaccine safety,[29] open reporting promotes public
confidence in the vaccine and the surveillance system, and can mitigate anti-vaccination
campaigns.[30] While provider recommendations drive immunisation,[6] public and
provider belief that regulatory systems are robust will be critical to achieve high COVID-19
immunisation rates required for herd immunity.[31]

Rapid engagement of a trained immunisation workforce with access to active vaccine safety
surveillance will be crucial for COVID-19 vaccine deployment. Pharmacists have been

19

medRxiv preprint doi: https://doi.org/10.1101/2020.12.14.20248212; this version posted December 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

recognised as qualified immunisers in many countries for more than ten years.[15] Two
systematic reviews have demonstrated pharmacists increase vaccination coverage when
compared to traditional (non-pharmacist) providers alone.[32,33] Several factors specific to
pharmacies including convenience, accessibility, extended opening hours, and the ability to
obtain a vaccination without prior appointment have been shown to increase immunisation
rates across the world.[14,15,32,33] It is likely pharmacies capture patients who would
otherwise avoid immunisation,[14] but this is not driven by cost: non-pharmacist immunisers
in Australia are partly funded by the Australian Government to provide immunisation
services, whereas pharmacists receive no remuneration. Yet patients who could access partly
or fully subsidised vaccines through a general practitioner choose to obtain, and pay for, their
immunisations from pharmacies.[14,15,34]

While COVID-19 vaccines will be free in Australia,[18] several factors beyond cost and
safety surveillance could influence uptake. During the first wave of COVID-19 infections
when caseload was high, the Australian Government launched a National Health Plan, to
protect both the public and the primary care workforce.[35] This resulted in a significant shift
to telehealth consultations, with high uptake in general practice,[35] although pharmacies
remained open as ‘essential services’ to the public to provide medicines and primary
care.[36] The active COVID-19 caseload at the time of vaccine deployment may not be
known,[18] nor the impact this might have on the available immunisation workforce. While
pharmacists in Australia are not expected to deliver COVID-19 immunisations during initial
deployment, they can still influence vaccine uptake through education and advocacy,[15,32]
deliver a range of routine vaccinations and provide critical surge capacity[37] including for
COVID-19 vaccines, and surveillance in the early event non-pharmacist immunisers are
overloaded or under lockdown. Pharmacists can capture patients who are fearful of

20

medRxiv preprint doi: https://doi.org/10.1101/2020.12.14.20248212; this version posted December 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

encountering acutely infectious individuals in clinic waiting rooms,[15] and should be
considered, with active surveillance on board, as early potential vaccinators for Australia.
Finally, suitably trained hospital-based pharmacists may also contribute via immunisation of
health care workers and others in hospitals.

The integrated system is not without limitations. Our active surveillance integration requires
Internet connectivity for the immunisation provider and mobile network connectivity for the
consumer. This may pose an issue for the global population, where Internet access is
estimated to be approximately 63%, with approximately 67% subscribed to mobile
services,[38] but is less of an issue in developed countries with broad coverage.

Approximately 10% of participants in this study chose not to participate in active surveillance
and did not receive SMS1. This may have been a feature of not wishing to participate in a
research project, rather than wishing to avoid monitoring, and is expected to be different in
the rollout of a COVID-19 vaccine. It is also important to note causality assessment as per the
WHO criteria is an essential component of any vaccine safety surveillance program.[39] This
is not achievable using our integrated system (only a temporal association is observed), nor is
it intended: the purpose is to provide near-real time surveillance, with a known denominator,
so that early vaccine safety signals can be identified. Causality assessments are within the
scope of the wider network, including AusVaxSafety and the NCIRS.

A key strength of this study was our examination of data flow, to ensure all immunisation
records transferred in the integrated pharmacy system. To the best of our knowledge this is
the only audit of data flow in an active surveillance system. We identified three key issues.
Firstly, the API did not identify records without sex recorded, and as a result, 21% of

21

medRxiv preprint doi: https://doi.org/10.1101/2020.12.14.20248212; this version posted December 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

immunisations were not automatically monitored in the first half of this study. This issue was
identified, the system was updated, and all records subsequently transferred. Future iterations
of the system should enforce recording of all patient data during the consent process.
Secondly, a small proportion of pharmacists used a paper-based system to record vaccination
encounters, and subsequently transposed those records to the electronic system. This may
have been a stop-gap measure during the unprecedented demand period of early COVID-19
activity, or it may represent usual practice. Records transferred more than three business days
after immunisation were not automatically monitored, and the reason for the paper system
was not elucidated. Thirdly, 3% of participants did not have a valid mobile phone number
recorded and also were not monitored. Attention should be given to identify whether
participants own a mobile phone, and if so, to accuracy in data entry.

22

medRxiv preprint doi: https://doi.org/10.1101/2020.12.14.20248212; this version posted December 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

CONCLUSION
We are on the cusp of a new period in immunisation. The crucial next step is to leverage
proven technology to enable broad scale vaccine deployment of any COVID-19 vaccines that
are approved for use, with a trained workforce enabled with active surveillance systems. We
have developed an integrated active vaccine safety surveillance system that is immediately
scalable to thousands of pharmacies in Australia and potentially globally. Lower proportions
of adverse events following immunisation in pharmacies compared to non-pharmacy sites
demonstrates pharmacies are a safe destination for immunisation, and may capture people
who would not otherwise obtain an immunisation. With an integrated system that facilitates
both reporting of the immunisation to the Australian Immunisation Register, as well as links
to national vaccine safety surveillance, pharmacists in Australia can contribute actively and
safely to all immunisation programs.

23

medRxiv preprint doi: https://doi.org/10.1101/2020.12.14.20248212; this version posted December 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

ACKNOWLEDGMENTS
The study was supported by a research grant provided by the J.M. O’Hara Research Fund of
the Pharmaceutical Society of Western Australia.
We are extremely grateful for the tremendous in-kind support provided by SmartVax and
MedAdvisor International and for their unending commitment and tireless efforts to conduct
and complete the study in the year 2020 – a year of significant disruption on a global scale.
We would also like to thank Ms Dani Li, Mr Craig Schnuriger, Mr Weyn Ong, Mr Daniel
Smith, Ms Karin Orlemann, and Ms Danae Perry, for their continued efforts and
contributions.

AUTHOR CONTRIBUTIONS
SMS conceptualized, designed and supervised the study, raised funding for the study, assisted
with data collection and analysis, interpreted the results, wrote the draft versions and
prepared the final version of the manuscript. GS performed the literature review, assisted
with data collection and interpretation of the results, and reviewed the manuscript. LN raised
funding for the study, assisted with study design and recruitment, interpreted the results, and
reviewed the manuscript. KT assisted with data collection, verified the underlying data,
performed data analysis, interpreted the results, prepared all charts, wrote part of the draft
versions, and reviewed the manuscript. KM assisted with data collection, verified the
underlying data, assisted with data analysis, interpreted the results, and reviewed the
manuscript. KL assisted with study design, raised funding and reviewed the manuscript. BK
performed the literature review, assisted with data collection and interpretation of the results,
and reviewed the manuscript. IP provided intellectual and technical input, provided access to
active surveillance, assisted with study supervision, data collection and analysis, interpreted
the results and reviewed the manuscript. AL provided intellectual input, provided access to

24

medRxiv preprint doi: https://doi.org/10.1101/2020.12.14.20248212; this version posted December 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

active surveillance, assisted with study supervision, data collection and analysis, interpreted
the results and reviewed the manuscript. All authors have read and approved the final version
of the manuscript.

DECLARATION OF CONFLICT OF INTEREST
AL and IP are Directors of SmartXData, of which SmartVax is a subsidiary. IP has received
funding from SmartXData for database development. The authors declare no other conflicts.

FUNDING SOURCE
The study was supported by a research grant provided by the J.M. O’Hara Research Fund of
the Pharmaceutical Society of Western Australia. The funders of this study had no role in the
study design, data collection, analysis, interpretation, recruitment or writing of the report.

25

medRxiv preprint doi: https://doi.org/10.1101/2020.12.14.20248212; this version posted December 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

REFERENCES
1.
World Health Organization. Draft landscape of COVID-19 candidate vaccines.
https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
(accessed Dec 2, 2020).
2.
COVAX: GAVI. https://www.gavi.org/covax-facility. (accessed Dec 2, 2020).
3.
Kochhar S, Salmon DA. Planning for COVID-19 vaccines safety surveillance.
Vaccine 2020;38:6194-8.doi:10.1016/j.vaccine.2020.07.013
4.
Kostoff RN, Briggs MB, Porter AL, et al. COVID-19 vaccine safety. Int J Mol Med
2020;46:1599-602.doi:10.3892/ijmm.2020.4733
5.
Krause M, Gruber M. Emergency use authorization of Covid vaccines - safety and
efficacy follow-up considerations. N Engl J Med
2020;383:e107.doi:10.1056/NEJMp2031373
6.
Blyth CC, Richmond PC, Jacoby P, et al. The impact of pandemic A(H1N1)pdm09
influenza and vaccine-associated adverse events on parental attitudes and influenza vaccine
uptake in young children. Vaccine 2014;32:4075-81.doi:10.1016/j.vaccine.2014.05.055
7.
Clothier HJ, Crawford NW, Russell M, et al. Evaluation of 'SAEFVIC', A
pharmacovigilance surveillance scheme for the spontaneous reporting of adverse events
following immunisation in Victoria, Australia. Drug Saf 2017;40:48395.doi:10.1007/s40264-017-0520-7
8.
Leeb A, Regan AK, Peters IJ, et al. Using automated text messages to monitor
adverse events following immunisation in general practice. Med J Aust 2014;200:4168.doi:10.5694/mja13.11166
9.
Cashman P, Macartney K, Khandaker G, et al. Participant-centred active surveillance
of adverse events following immunisation: a narrative review. International Health
2017;9:164-76.doi:10.1093/inthealth/ihx019
10.
Bettinger JA, De Serres G, Valiquette L, et al. 2017/18 and 2018/19 seasonal
influenza vaccine safety surveillance, Canadian National Vaccine Safety (CANVAS)
Network. Euro Surveill 2020;25(22).doi:0.2807/1560-7917.ES.2020.25.22.1900470
11.
Cashman P, Moberley S, Dalton C, et al. Vaxtracker: Active on-line surveillance for
adverse events following inactivated influenza vaccine in children. Vaccine 2014;32:55038.doi:10.1016/j.vaccine.2014.07.061
12.
AusVaxSafety: National Centre for Immunisation Research and Safety.
http://ncirs.org.au/our-work/ausvaxsafety. (accessed Dec 2, 2020).
13.
Adverse event monitoring internationally. Therapeutic Goods Administration.
https://www.tga.gov.au/adverse-event-monitoring-internationally 2020. (accessed Dec 2,
2020).
14.
Burt S, Hattingh L, Czarniak P. Evaluation of patient satisfaction and experience
towards pharmacist-administered vaccination services in Western Australia. Int J Clin
Pharm. 2018;40:1519-27.doi:10.1007/s11096-018-0738-1
15.
Poudel A, Lau ETL, Deldot M, et al. Pharmacist role in vaccination: evidence and
challenges. Vaccine 2019;37:5939-45.doi:10.1016/j.vaccine.2019.08.060
16.
International Federation of Pharmacy. An overview of current pharmacy impact on
immunisation: a global report.
https://www.fip.org/files/fip/publications/FIP_report_on_Immunisation.pdf. (accessed Dec 2,
2020).
17.
McDerby NC, Kosari S, Bail KS, et al. Pharmacist-led influenza vaccination services
in residential aged care homes: A pilot study. Australas J Ageing 2019;38:132-5.doi:
10.1111/ajag.12611

26

medRxiv preprint doi: https://doi.org/10.1101/2020.12.14.20248212; this version posted December 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

18.
Australian Government Department of Health. Australian COVID-19 vaccination
policy. https://www.health.gov.au/sites/default/files/documents/2020/11/australian-covid-19vaccination-policy_1.pdf. (accessed Dec 2, 2020).
19.
Centers for Disease Control and Prevention. Ensuring the safety of COVID-19
vaccines in the United States: United States Center for Diseases Control; 2020.
https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety.html. (accessed Dec 2, 2020).
20.
Nadeem MF, Samanta S, Mustafa F. Is the paradigm of community pharmacy practice
expected to shift due to COVID-19? Res Social Adm Pharm 2021;17:2046-8.doi:
10.1016/j.sapharm.2020.05.021.
21.
MedAdvisor 2020. https://www.medadvisor.com.au/Home/Landing. (accessed Dec 2,
2020).
22.
The University of Western Australia. New program to monitor adverse effects of new
vaccines. https://www.uwa.edu.au/news/Article/2020/March/New-program-to-monitoradverse-effects-of-new-vaccines. (accessed Dec 2, 2020).
23.
Westphal DW, Williams SA, Leeb A, et al. Continuous active surveillance of adverse
events following immunisation using SMS technology. Vaccine 2016;34:33505.doi:10.1016/j.vaccine.2016.05.015
24.
von Elm E, Altman DG, Egger M, et al. Strengthening the Reporting of Observational
Studies in Epidemiology (STROBE) statement: guidelines for reporting observational
studies. BMJ 2007;335(7624):806-8.doi:10.1136/bmj.39335.541782.AD
25.
Chandler RE. Optimizing safety surveillance for COVID-19 vaccines. Nat Rev
Immunol 2020;20:451-2.doi:10.1038/s41577-020-0372-8
26.
Vette K, Dalton L, Dey A, et al. Review of pharmacist vaccination reporting to the
AIR Final report. National Centre for Immunisation Research and Surveillance. 2020
https://ncirs.org.au/sites/default/files/202006/Review%20of%20pharmacist%20vaccination%20reporting%20to%20the%20AIR_Final
%20report_May%202020.pdf (acessed Dec 2, 2020).
27.
Dhanda S, Osborne V, Lynn E, et al. Postmarketing studies: can they provide a safety
net for COVID-19 vaccines in the UK? BMJ Evid Based Med 2020. doi:10.1136/bmjebm2020-111507.
28.
Australian Government Ministers Department of Health. Strengthening Australia's
immunisation program. 2020 https://www.health.gov.au/ministers/the-hon-greg-huntmp/media/strengthening-australias-immunisation-program. (accessed, Dec 4, 2020).
29.
Wilson SL, Wiysonge C. Social media and vaccine hesitancy. BMJ Glob Health
2020;5.doi:10.1136/bmjgh-2020-004206.
30.
Stokes BP. Ministerial Review into the Public Health Response into the Adverse
Events to the Seasonal Influenza Vaccine. Government of Western Australia, Department of
Health; 2010.
http://www.parliament.wa.gov.au/publications/tabledpapers.nsf/displaypaper/3812402ae272b
7e74cd6982e4825777e000af344/$file/2402+-+seasonal+influenza+vaccine.pdf. (accessed
Dec 2, 2020).
31.
Lazarus JV, Ratzan SC, Palayew A, et al. A global survey of potential acceptance of a
COVID-19 vaccine. Nat Med 2020doi:10.1038/s41591-020-1124-9.
32.
Baroy J, Chung D, Frisch R, et al. The impact of pharmacist immunization programs
on adult immunization rates: A systematic review and meta-analysis. J Am Pharm Assoc
(2003) 2016;56:418-26.doi:10.1016/j.japh.2016.03.006
33.
Isenor JE, Kervin MS, Halperin DM, et al. Pharmacists as immunizers to Improve
coverage and provider/recipient satisfaction: A prospective, Controlled Community
Embedded Study with vaccineS with low coverage rates (the Improve ACCESS Study):

27

medRxiv preprint doi: https://doi.org/10.1101/2020.12.14.20248212; this version posted December 16, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Study summary and anticipated significance. Can Pharm J (Ott) 2020;152:88-94.doi:
10.1177/1715163519900221
34.
Anderson C, Thornley T. “It’s easier in pharmacy”: why some patients
prefer to pay for flu jabs rather than use the National Health Service. BMC Health Serv Res
2014;14:35.doi:10.1186/1472-6963-14-35
35.
Desborough J, Hall Dykgraaf S, Toca L, et al. Australia's national COVID-19 primary
care response. Med J Aust 2020;213:104-6.e1.doi:10.5694/mja2.50693
36.
Cadogan CA, Hughes CM. On the frontline against COVID-19: community
pharmacists' contribution during a public health crisis. Res Social Adm Pharm 2020;17:20325.doi:10.1016/j.sapharm.2020.03.015
37.
Patel C, Dalton L, Dey A, et al. Letter: Impact of the COVID-19 pandemic on
pharmacist-administered vaccination services. Res Social Adm Pharm 2021;17:2040-1.doi:
10.1016/j.sapharm.2020.08.021
38.
GSMA. The mobile economy. https://www.gsma.com/mobileeconomy/. (accessed
Dec 2, 2020).
39.
Joshi J, Das MK, Polpakara D, et al. Vaccine safety and surveillance for adverse
events following immunization (AEFI) in India. Indian J Pediatr 2018;85:13948.doi:10.1007/s12098-017-2532-9

28

